Compare Adaptive Biotechnologies Corp (ADPT) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Deckers Outdoor Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.05B), while Deckers Outdoor Corp trades at $94 (market cap $13.27B). The key difference: Deckers Outdoor Corp is far larger — about 3.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | DECK | |
|---|---|---|
Market Cap | $4.05B | $13.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $123.91 |
52-Week Low | $12.15 | $79.54 |
Enterprise Value | $4.12B | $12.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Deckers Outdoor (DECK) trades at $97.46, down 0.42% with bearish technical signals but strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $0.96 beating expectations of $0.81. Revenue grew to $4.99 billion in 2025 with impressive 18.36% net margin and 42.56% ROE. Analyst consensus remains positive with 45% buy ratings and $122.40 price target, though recent guidance concerns caused a 6% selloff.
DECK offers compelling value with a 13.86 P/E ratio below industry averages, supported by HOKA and UGG brand strength. Key risks include tariff headwinds, brand concentration, and execution challenges. The stock presents a growth opportunity at current levels but faces near-term volatility from macroeconomic pressures and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
